Abeona Therapeutics Inc.

For Q2 2026, Abeona reported net ZEVASKYN revenue of $11.4 million, up 31% quarter over quarter, or $2.7 million, from $8.7 million in Q1 2026. The company treated 5 patients in the quarter, but recognized revenue for only 4 treatments because 1 batch had cell yield below the threshold for revenue recognition. R&D expense was $5 million versus $9.6 million in Q1 2026; SG&A was $15.8 million versus $19.5 million in Q1 2026. Net loss was $20.2 million, or $0.35 per basic and diluted share, versus a net loss of $17.1 million, or $0.30 per share, in Q1 2026. Cash, cash equivalents and short-term investments were $146.8 million as of June 30, 2026. Looking ahead, management did not give formal revenue guidance, but said future disclosures will focus on patients treated during the quarter and net revenue recognized, and reiterated its goal of reaching a sustainable cash flow positive model by maintaining a consistent cadence of patient treatments.

Vishwas Seshadri framed the quarter as evidence that ZEVASKYN has a substantial commercial opportunity, but also said the launch is revealing real-world complexities unique to a surgically applied autologous cell therapy. He emphasized that the company is building clinical conviction through early treatment outcomes, expanding the QTC network, and improving access and reimbursement. His tone was confident but pragmatic, repeatedly stressing that the business is still learning how to convert patient interest into consistent revenue-generating treatments.

Joseph Vazzano focused on transparency in reporting and said Abeona will now anchor quarterly disclosures around completed operational achievements: patients treated and net revenue recognized. He cited Q2 net revenue of $11.4 million, R&D of $5 million, SG&A of $15.8 million, and a net loss of $20.2 million, while highlighting the $146.8 million cash balance at quarter-end. He also said gross margins should improve with scale because most manufacturing costs are fixed, estimating a steady-state gross margin of about 85% to 90% once full operating capacity is reached.

Analysts pressed management on when QTCs like Lurie and Stanford might reach a cadence of 1 patient per month, how to think about manufacturing yields and whether low-yield/out-of-spec batches are isolated, and how long it takes new QTCs to begin treating patients. Management said the 1-patient-per-month level is something they expect once centers reach steady state, but timing remains hard to predict. On manufacturing, they said the low-yield event appears rare so far, average commercial yield is about 9 sheets per lot, and the out-of-spec issue involved a keratinocyte identity test that they are discussing with FDA. They also said site activation to treatment can be as short as CHOP's May-to-July path, but in other cases may take 12 months or more.